US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ヨーロッパ
EU
Sonaecom SGPS SA (SNC) 銘柄情報

Sonaecom SGPS SA (SNC)

2.92

0.02

(0.69%)

終了 6月6日 12:30AM

Sonaecom SGPS SA (SNC) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

2.92

( 0.69% )

買値

2.84

売値

2.92

出来高

2,710

2.82 日の範囲 2.94

2.32 52 週間の範囲 3.24

時価総額

前日終値

2.90

始値

2.90

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

13,042 €

発行済株式数

305,769,023

配当利回り

0.08

PER

14.79

1 株当たり利益 (EPS)

0.2

歳入

19.41M

純利益

59.47M

Sonaecom, SGPS, S.A., together with its subsidiaries, operates in technology, media, and telecommunications areas worldwide. The company provides consultancy services in the area of information systems; and sells licensed software. It also engages in the editing, composition, and publication of peri... Sonaecom, SGPS, S.A., together with its subsidiaries, operates in technology, media, and telecommunications areas worldwide. The company provides consultancy services in the area of information systems; and sells licensed software. It also engages in the editing, composition, and publication of periodical and non-periodical materials, as well as exploration of radio and TV stations and studios; consulting business, advisory in retail segments, industry and services. In addition, the company is involved in the development, installation, implementation, training, and maintenance of systems and software products; rental of equipment; consulting business; industries and trade of electronic equipment and software. Further, it invests in and manages venture capital and venture capital funds. The company was incorporated in 1988 and is headquartered in Cidade da Maia, Portugal. Sonaecom, SGPS, S.A. operates as a subsidiary of Sontel B.V. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.sonaecom.pt

本社

Cidade Da Maia, Portugal

設立

1988

Sonaecom SGPS SA is listed in the sector of the ユーロネクスト with ticker SNC. The last closing price for Sonaecom SGPS was 2.90 €. Over the last year, Sonaecom SGPS shares have traded in a share price range of 2.32 € to 3.24 €.

Sonaecom SGPS currently has 305,769,023 shares in issue. The market capitalisation of Sonaecom SGPS is 892.85 € million. Sonaecom SGPS has a price to earnings ratio (PE ratio) of 14.79.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.04	-1.35135135135	2.96	2.96	2.68	6379	2.91315921	DE
4	-0.04	-1.35135135135	2.96	2.98	2.68	3742	2.93275043	DE
12	-0.1	-3.31125827815	3.02	3.04	2.68	4412	2.94861164	DE
26	0	0	2.92	3.04	2.68	9529	2.97036304	DE
52	0.48	19.6721311475	2.44	3.24	2.32	6915	2.93358752	DE
156	0.45	18.2186234818	2.47	3.24	2.06	4243	2.73133285	DE
260	1.34	84.8101265823	1.58	3.24	1.54	10355	2.27345604	DE

SNC - Frequently Asked Questions (FAQ)

What is the current Sonaecom SGPS SA share price?

The current share price of Sonaecom SGPS SA is 2.92 €

How many Sonaecom SGPS SA shares are in issue?

Sonaecom SGPS SA has 305,769,023 shares in issue

What is the market cap of Sonaecom SGPS SA?

The market capitalisation of Sonaecom SGPS SA is EUR 892.85M

What is the 1 year trading range for Sonaecom SGPS SA share price?

Sonaecom SGPS SA has traded in the range of 2.32 € to 3.24 € during the past year

What is the PE ratio of Sonaecom SGPS SA?

The price to earnings ratio of Sonaecom SGPS SA is 14.79

What is the cash to sales ratio of Sonaecom SGPS SA?

The cash to sales ratio of Sonaecom SGPS SA is 46.63

What is the registered address of Sonaecom SGPS SA?

The registered address for Sonaecom SGPS SA is Lugar de Espido, Cidade da Maia, Norte, 4470-177

What is the Sonaecom SGPS SA website address?

The website address for Sonaecom SGPS SA is www.sonaecom.pt

US Market News

US Market News 6分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 6分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 8分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 11分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 12分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 15分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 15分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 16分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 19分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 20分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 20分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 21分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 23分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 24分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 24分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 24分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 25分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 25分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 25分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 26分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 29分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 31分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

WisdomTree Japan Equity ...

Micron Technology

Canadian Equity Growth C...

Sterling vs BBD

Max Resource (ID)

Renegade Gold (QB)

Viper Networks (ID)

Novo Nordisk (PK)

Prosegur Cia de Seguridad (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。